Ponatinib Production Cost Reports

The report provides a detailed analysis essential for establishing a ponatinib production plant. It encompasses all critical aspects necessary for ponatinib production, including the cost of ponatinib production, ponatinib plant cost, ponatinib production costs, and the overall ponatinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a ponatinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ponatinib is a targeted cancer medicine designed for adults battling chronic myeloid leukaemia (CML). It is utilised in its early chronic phase, more aggressive accelerated phase, or dangerous blast phase, as well as for Philadelphia chromosome-positive acute lymphoblastic leukaemia. It belongs to a class of drugs called tyrosine kinase inhibitors that specifically block the faulty BCR-ABL1 protein fuelling these blood cancers. It is effective for patients who no longer respond to earlier treatments like imatinib or dasatinib, or those with the tough T315I mutation that resists most other options. It is approved after strong clinical trial results showing deep remissions even in heavily treated cases. It is combined with chemotherapy to improve outcomes before potential stem cell transplants.

The market for ponatinib is driven by rising chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) diagnoses. Its utilisation in especially resistant cases needing potent third-generation tyrosine kinase inhibitors fuels its demand. Its use with chemo and oncology infrastructure growth in North America, Europe, and the Asia-Pacific boosts its market. The high costs as a premium orphan oncology drug, supplied by specialised API production under strict GMP, and regulatory needs for clinical use affect industrial ponatinib procurement. The reimbursement for rare blood cancers, insurance prior authorisations, lack of generics pre-patent expiry, and competition from other TKIs like dasatinib affect its availability.

Raw Material for Ponatinib Production

According to the ponatinib production plant project report, the key raw materials used in the production of ponatinib include imidazo[1,2-b]pyridazine, N-halogenated succinimide, and 3-iodo-4-R-benzoate.

Production Process of Ponatinib

The extensive ponatinib production cost report consists of the following major industrial production process:

1. From imidazo[1,2-b]pyridazine: The production process of ponatinib synthesis involves several steps. The process starts with imidazo[1,2-b]pyridazine reacting with N-halogenated succinimide in an organic solvent like chloroform at reflux to form 3-halogenated imidazo[1,2-b]pyridazine. After that, 3-iodo-4-R-benzoate goes through Sonogashira coupling with trimethylsilyl acetylene using Pd/Cu catalysts in ethyl acetate to yield 4-R-3-trimethylsilylethynyl benzoate. This is followed by deprotection with K2CO3 in methanol to give 3-ethynyl-4-R-benzoate. This alkyne then couples with the 3-haloimidazo[1,2-b]pyridazine via another Pd/Cu-catalysed reaction in N-methylpyrrolidone to produce 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-R-benzoate.Finally, the ester goes through base-promoted aminolysis with 4-((4-methylpiperazin-1-yl)methylene)-3-trifluoromethylaniline to obtain ponatinib.

Ponatinib is a small-molecule kinase inhibitor with the chemical formula C29H27F3N6O and a molecular weight of 532.56 g/mol. It appears as a white to off-white solid powder. It exhibits low water solubility (practically insoluble, <0.1 mg/mL) but good permeability (BCS class II/IV), with a logP around 5.2, indicating high lipophilicity. It has a melting point above 200 degree Celsius, and stability under neutral pH conditions suitable for oral tablet formulation. Its structure features an imidazo[1,2-b]pyridazine core linked via ethynyl to a substituted benzamide, enabling potent BCR-ABL binding, with no notable vapour pressure or explosive properties.